These inhibitors work by binding to the ATP-binding site of aurora kinases, thereby preventing their activation. This inhibition leads to a series of events including mitotic arrest, chromosome misalignment, and ultimately cell death. The specificity of these inhibitors for aurora kinases over other kinases is crucial for minimizing side effects and maximizing therapeutic efficacy.
